Vishal Manchanda, Pharma Analyst at Systematix Group, said the US remains dependent on Indian generic medicines, which helps mitigate long-term trade risks from probes such as the Section 232 investigation.
Vishal Manchanda, Pharma Analyst at Systematix Group, said the US remains dependent on Indian generic medicines, which helps mitigate long-term trade risks from probes such as the Section 232 investigation.